HC Wainwright Lowers Immunic (NASDAQ:IMUX) Price Target to $5.00

Immunic (NASDAQ:IMUX) had its price objective reduced by stock analysts at HC Wainwright from $8.00 to $5.00 in a report released on Monday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s price objective would suggest a potential upside of 367.29% from the company’s current price.

A number of other brokerages have also recently commented on IMUX. Brookline Capital Acquisition upgraded shares of Immunic to a “strong-buy” rating in a research note on Tuesday, February 3rd. Weiss Ratings restated a “sell (e+)” rating on shares of Immunic in a research report on Monday, December 29th. Roth Mkm started coverage on Immunic in a research report on Friday, November 7th. They issued a “buy” rating and a $3.00 price target on the stock. Chardan Capital raised Immunic to a “strong-buy” rating in a report on Wednesday, November 19th. Finally, D. Boral Capital lowered their target price on shares of Immunic from $8.00 to $4.00 and set a “buy” rating on the stock in a report on Friday, February 13th. Three investment analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $6.00.

Immunic Price Performance

Shares of Immunic stock opened at $1.07 on Monday. Immunic has a 52-week low of $0.51 and a 52-week high of $1.35. The firm has a market capitalization of $139.59 million, a PE ratio of -1.53 and a beta of 1.46. The company’s fifty day moving average price is $0.72 and its two-hundred day moving average price is $0.76.

Immunic (NASDAQ:IMUX) last released its quarterly earnings data on Thursday, February 26th. The company reported ($0.12) EPS for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.02). Analysts predict that Immunic will post -0.94 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Qube Research & Technologies Ltd bought a new stake in Immunic during the 3rd quarter worth about $29,000. Focus Partners Wealth raised its stake in shares of Immunic by 1.5% in the third quarter. Focus Partners Wealth now owns 2,581,587 shares of the company’s stock worth $2,276,000 after acquiring an additional 39,063 shares during the last quarter. Two Sigma Investments LP acquired a new position in shares of Immunic during the third quarter worth approximately $52,000. Squarepoint Ops LLC grew its stake in shares of Immunic by 29.9% during the fourth quarter. Squarepoint Ops LLC now owns 352,875 shares of the company’s stock valued at $188,000 after purchasing an additional 81,301 shares during the last quarter. Finally, Jane Street Group LLC grew its stake in shares of Immunic by 46.8% during the fourth quarter. Jane Street Group LLC now owns 286,677 shares of the company’s stock valued at $153,000 after purchasing an additional 91,346 shares during the last quarter. Institutional investors and hedge funds own 51.82% of the company’s stock.

About Immunic

Immunic, Inc is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to treat chronic inflammatory and autoimmune diseases as well as certain cancers. The company’s research strategy centers on small-molecule immunology, aiming to offer targeted treatments with improved safety and tolerability profiles. By modulating key signaling pathways within the immune system, Immunic seeks to address underlying disease mechanisms and achieve durable therapeutic benefits for patients.

Immunic’s lead product candidate, vidofludimus calcium (IMU-838), is an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor in Phase 2 clinical development for conditions including ulcerative colitis, Crohn’s disease and relapsing multiple sclerosis.